论文部分内容阅读
采用酶联免疫法测定分化抑制因子nm23-H1蛋白在80例慢性粒细胞白血病(CML)患者(观察组)和30例健康志愿者(对照组)血浆中的含量。结果观察组慢性期(CML-CP)nm23-H1蛋白血浆水平与对照组无显著差异,加速期(CML-AP)、急变期(CML-BP)明显高于对照组(P<0.001),CML-BP明显高于CML-AP。认为nm23-H1蛋白在CML血浆中的表达水平与疾病进展有关,nm23-H1蛋白表达水平可为CML早期诊断、临床分期及预后判断提供新的评价手段及实验室依据。
Enzyme-linked immunosorbent assay was used to determine the plasma levels of nm23-H1 protein in 80 patients with chronic myeloid leukemia (CML) and 30 healthy volunteers (control group). Results The serum level of nm23-H1 protein in chronic phase (CML-CP) of observation group was not significantly different from that in control group. The levels of CML-AP and CML-BP in the observation group were significantly higher than those in control group (P <0.001) -BP was significantly higher than CML-AP. It is considered that the expression level of nm23-H1 protein in CML plasma is related to the progress of the disease. The expression of nm23-H1 protein provides a new evaluation method and laboratory evidence for the early diagnosis, clinical staging and prognosis of CML.